Chemotherapy-Free triple attack on blood cancer shows promise
NCT ID NCT07299149
Summary
This study is testing a new combination of three targeted drugs (zanubrutinib, obinutuzumab, and lenalidomide) for people with follicular lymphoma who haven't had any previous treatment. The goal is to see if this chemotherapy-free approach can effectively control the cancer while causing fewer side effects than traditional treatments. Researchers will enroll 34 patients in China to measure how well the cancer responds and how safe the treatment is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin 300020
Tianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.